Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

• Κύριοι συγγραφείς: E. D. Moreira (Συγγραφέας), A. R. Giuliano (Συγγραφέας), J. de Hoon (Συγγραφέας), O.-E. Iversen (Συγγραφέας), E. A. Joura (Συγγραφέας), J. Restrepo (Συγγραφέας), P. Van Damme (Συγγραφέας), C. Vandermeulen (Συγγραφέας), M. C. Ellison (Συγγραφέας), A. Krick (Συγγραφέας), C. Shields (Συγγραφέας), B. Heiles (Συγγραφέας), A. Luxembourg (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2018-02-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) v...